Allogeneic Hematopoietic Cell Transplantation for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 9, 2008, Pages 949-958

  Abou Mourad, Yasser R ^a   Fernandez, Hugo F ^b   Kharfan Dabaja, Mohamed A ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; Imatinib; Philadelphia positive acute lymphoblastic leukemia; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; IMATINIB; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NILOTINIB; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DIARRHEA; DONOR LYMPHOCYTE INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HLA MATCHING; HUMAN; HYPERBILIRUBINEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUTROPENIA; OPTIMAL DRUG DOSE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PROGNOSIS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ADULT; ALGORITHMS; DISEASE-FREE SURVIVAL; GLUCOCORTICOIDS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 49649096554     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.04.012     Document Type: Review

References (57)

1. Larson R.A., Dodge R.K., Burns C.P., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85 (1995) 2025-2037
2. Kantarjian H.M., O'Brien S., Smith T.L., et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18 (2000) 547-561
3. Hoelzer D., and Gökbuget N. Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol 36 (2000) 49-58
4. Radich J.P. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 15 (2001) 21-36
5. Thomas X., Danaïla C., Le Q.H., et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 15 (2001) 1811-1822
6. Avivi I., and Goldstone A.H. Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant 31 (2003) 623-632
7. Goldstone A.H., Prentice H.G., Durrant I.J., et al. Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph +) acute lymphoblastic leukemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993). Blood 98 (2001) 856a
8. Chao N.J., Blume K.G., Forman S.J., and Snyder D.S. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 85 (1995) 3353-3354
9. Dombret H., Gabert J., Boiron J.M., et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 100 (2002) 2357-2366
10. Snyder D.S., Nademanee A.P., O'Donnell M.R., et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 13 (1999) 2053-2058
11. Stockschläder M., Hegewisch-Becker S., Krüger W., et al. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 16 (1995) 663-667
12. Barrett A.J., Horowitz M.M., Ash R.C., et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 79 (1992) 3067-3070
13. Sierra J., Radich J., Hansen J.A., et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 90 (1997) 1410-1414
14. Lee S., Kim D.W., Cho B., et al. Risk factors for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 120 (2003) 145-153
15. Nowell P.C., and Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132 (1960) 1497
16. Clark S.S., McLaughlin J., Timmons M., et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 239 (1988) 775-777
17. Faderl S., Kantarjian H.M., Talpaz M., and Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91 (1998) 3995-4019
18. Moorman A.V., Harrison C.J., Buck G.A., et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109 (2007) 3189-3197
19. Lugo T.G., Pendergast A.M., Muller A.J., and Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 (1990) 1079-1082
20. Ottmann O.G., Druker B.J., Sawyers C.L., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 (2002) 1965-1971
21. Scheuring U.J., Pfeifer H., Wassmann B., et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia 17 (2003) 1700-1706
22. Shimoni A., Kröger N., Zander A.R., et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 17 (2003) 290-297
23. Wassmann B., Pfeifer H., Scheuring U., et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 16 (2002) 2358-2365
24. Thomas D.A., Faderl S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 (2004) 4396-4407
25. Thomas D.A., Kantarjian H.M., Ravandi F., et al. Long-term follow-up after frontline therapy with hyper-CVAD and imatinib mesylate regimen in adults with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 110 (2007) 10a
26. Towatari M., Yanada M., Usui N., et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104 (2004) 3507-3512
27. Lee S., Kim Y.J., Min C.K., et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105 (2005) 3449-3457
28. de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109 (2007) 1408-1413
29. Wassmann B., Pfeifer H., Goekbuget N., et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 108 (2006) 1469-1477
30. Fielding A.K., Richards S.M., Lazarus H.M., et al. Does imatinib change the outcome in Philapdelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study. Blood 110 (2007) 10a
31. Martin T.G., and Gajewski J.L. Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adults. Hematol Oncol Clinic North Am 15 (2001) 79-120
32. Wassmann B., Pfeifer H., Goekbuget N., et al. Early prediction of response in patients with relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib. Blood 103 (2004) 1495-1498
33. Druker B., Sawyers C., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (2001) 1038-1042
34. Carpenter P.A., Snyder D.S., Flowers M.E., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109 (2007) 2791-2793
35. Wassmann B., Pfeifer H., Stadler M., et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 106 (2005) 458-463
36. Radich J., Gehly G., Lee A., et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 89 (1997) 2602-2609
37. Carter T.A., Wodicka L.M., Shah N.P., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102 (2005) 11011-11016
38. Tokarski J.S., Newitt J.A., Chang C.Y., et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66 (2006) 5790-5797
39. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47 (2004) 6658-6661
40. Brave M., Goodman V., Kaminskas E., et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14 (2008) 352-359
41. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
42. Ottmann O., Dombret H., Martinelli G., et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110 (2007) 2309-2315
43. Porkka K., Simonsson B., Dombret H., et al. Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015). Blood 110 (2007) 826a
44. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
45. Mughal T.I., and Goldman J.M. Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia. Clin Lymphoma Myeloma Suppl 2 (2007) S81-S84
46. Ravandi F., Thomas D., Kantarjian H., et al. Phase II study of combination of the hyper-CVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB). Blood 110 (2007) 828a
47. Golemovic M., Verstovsek S., Giles F., et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11 (2005) 4941-4947
48. Verstovsek S., Golemovic M., Kantarjian H., et al. AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104 (2005) 1230-1236
49. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006) 2542-2551
50. Ottmann O.G., Larson R.A., Kantarjian H.M., et al. Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib. Blood 110 (2007) 828a
51. Ottmann O.G., and Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2005) 118-122
52. Ottmann O.G., Wassmann B., Pfeifer H., et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 109 (2007) 2068-2076
53. Delannoy A., Delabesse E., Lheritier V., et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 20 (2006) 1526-1532
54. Brandwein J.M., Gupta V., Wells R.A., et al. Treatment of elderly patients with acute lymphoblastic leukemia-evidence for a benefit of imatinib in BCR-ABL positive patients. Leuk Res 29 (2005) 1381-1386
55. Vignetti M., Fazi P., Cimino G., et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 109 (2007) 3676-3678
56. Foa R., Vignetti M., Vitale A., et al. Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph+ acute lymphoblastic leukemia (ALL) patients: interim analysis of the GIMEMA prospective study LAL1205. Blood 110 (2007) 10a
57. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 (2006) 460-466